• Physicians
  • By Specialty
  • By Name
  • By Language
• Medical Services
• Primary Care Centers
  • Centerville Health Center
  • Greenwood Health Center (Midvale)
  • Madsen Health Center (SLC)
  • Parkway Health Center (Orem)
  • Redstone Health Center (Park City)
  • Redwood Health Center (South SLC)
  • South Jordan Health Center
  • Sugar House Health Center
  • Stansbury Health Center (Tooele)
  • Urgent Care / After Hours
  • Westridge Health Center (West Valley City)
• Hospitals & Specialty Centers
  • University Hospital & Clinics
  • Cardiovascular Center
  • Clinical Neurosciences Center
  • Huntsman Cancer Hospital
  • Moran Eye Center
  • Rehabilitation Center
  • University Neuropsychiatric Institute
  • University Orthopaedic Center
  • Utah Diabetes Center
  • Other Specialty Centers

Psoriasis

The Department of Dermatology also conducts numerous clinical trials investigating new treatments for psoriasis. UPCOMING STUDIES, listed below, will be enrolling soon. Patients who have psoriasis who are interested in participating in a clinical study can call 801-581-6477 (Melissa). ONGOING STUDIES are no longer enrolling new patients.

Upcoming Studies

A Multicenter, Open Registry Of Patients With Psoriasis Who Are Candidate For Systemic Therapy Including Biologics (PSOLAR). Sponsor: Centocor

This is an 8 year study that will evaluate the long-term outcomes of patients who are candidates for systemic therapies including biologics. Current status: not yet ready to enroll

Eligibility: must be at least age 18, have psoriasis, and be a CANDIDATE for phototherapy or systemic therapies, and be willing to do a study visit every 6 months for up to 8 years.

A Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study To Assess The Efficacy And Safety Of Doxercaciferol Capsules In The Treatment Of Subjects With Moderate To Severe Chronic Plaque Psoriasis. (Sponsor: Genzyme; Protocol Name: HECTPS02507)

This is a study testing an oral vitamin D analog at different doses or placebo. Candidates for the study must be at least 18 years old, have moderate-to-severe plaque type psoriasis, and must meet other inclusion criteria to be eligible for the study.

Current status: not yet ready to enroll

Ongoing Studies

These studies are listed for interest only and are not enrolling new patients.

• A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing The Safety And Efficacy Of Two Dosing Regimens Of ABT-874 To Placebo In Subjects With Moderate To Severe Chronic Plaque Psoriasis” (Sponsor: Abbott; Protocol Number: M06-890)
• A Multicenter Open-Label Continuation Study In Moderate To Severe Chronic Plaque Psoriasis Subjects Who Completed A Preceding Psoriasis Clinical Study With Adalimumab (Sponsor: Abbott, Study Name Abbott M03-658)
• A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial Evaluating The Efficacy And Safety Of CNTO 1275 In The Treatment Of Subjects With Moderate To Severe Plaque Type Psoriasis. (Sponsor: Centocor; Protocol Name: C0743T09)
• A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 And Etanercept For The Treatment Of Moderate To Severe Plaque Psoriasis.  (Sponsor: Centocor;  Protocol Name: C0743T12)